Generation of Cell Banks and Biomarker Isolation From Patients With Amyotrophic Lateral Sclerosis (ALS) (HCD-SLA)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Total Enrollment

50 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-09-01

Study Completion Date

2026-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this research is to establish different cell banks from patients with amyotrophic lateral sclerosis (ALS).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Validation of Biomarkers in Amyotrophic Lateral Sclerosis (ALS)

NCT00677768

Amyotrophic Lateral Sclerosis Lou Gehrig's Disease Primary Lateral Sclerosis +2 more

COMPLETED

Target ALS Biomarker Study; Longitudinal Biofluids, Clinical Measures, and At Home Measures

NCT05137665

Amyotrophic Lateral Sclerosis Movement Disorders Degenerative Disorder +1 more

RECRUITING

Imaging and BioFluid Biomarkers in Amyotrophic Lateral Sclerosis

NCT02559869

Amyotrophic Lateral Sclerosis (ALS)

COMPLETED

sCD163 in ALS Patients

NCT02325375

Amyotrophic Lateral Sclerosis

COMPLETED

Establishment of a Tissue Bank (Blood, CSF) for the Understanding of Motor Neuron Disease (MND)

NCT01950910

Amyotrophic Lateral Sclerosis

TERMINATED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The objective of this research is to:

* Create banks of skin fibroblasts from skin biopsy samples
* Create banks of urine-derived cells (UDCs) from urine samples
* Build a collection of blood samples to enable isolation of biomarkers.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Amyotrophic Lateral Sclerosis (ALS)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

ALS patients

sampling blood

Intervention Type OTHER

3 types of sampling : urine, skin and blood.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

sampling blood

3 types of sampling : urine, skin and blood.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Subjects over 18 years old;
* Subjects who have given their consent and signed an informed, free and express consent form;
* Subjects with diagnosed ALS;
* Subjects affiliated to or benefiting from a social security scheme.

Exclusion Criteria

* Subjects with contraindications to the collection of biological samples (blood, skin, urine).
* Subjects undergoing treatment likely to affect hemostasis (anticoagulants, platelet anti-aggregants, etc.) in the month prior to inclusion and during the study;
* Subjects with hereditary or acquired haemostasis disorders;
* Subjects who have undergone physical treatment (radiotherapy, etc.) on the area to be biopsied in the last 6 months;
* Lidocaine-intolerant subjects;
* Subjects who have reached the age of majority and are subject to a protective measure or are unable to express their consent.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No